VVP
TRAW icon

Venture Visionary Partners’s Traws Pharma TRAW Stock Holding History

Venture Visionary Partners’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-27
Closed -$3K – 179
2019
Q4 		$3K Buy
+27
New +$5.04K ﹤0.01% 169

Other funds holding TRAW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HWA
Hillcrest Wealth Advisors Hazlet, New Jersey $279M AUM 21.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
QP
Quilter Plc London, United Kingdom $5.7B AUM 21.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Venture Visionary Partners's TRAW Position: Q1 2020 in Review

Venture Visionary Partners sold out of Traws Pharma (TRAW) in Q1 2020, closing a stake of 27 shares — an estimated $3K sold.

Venture Visionary Partners first reported a position in TRAW in Q4 2019 and held it in 1 quarter. The position peaked at $3K in Q4 2019. 21 funds tracked by Wall St. Rank hold TRAW as of Q1 2020.

  • Venture Visionary Partners reported no remaining Traws Pharma position as of Q1 2020 after selling out during the quarter.
  • Venture Visionary Partners sold 27 Traws Pharma shares in Q1 2020, an estimated $3K.
  • Venture Visionary Partners first reported a position in Traws Pharma in Q4 2019 and held it in 1 quarter.
  • Venture Visionary Partners's Traws Pharma position peaked at $3K in Q4 2019.
  • 21 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2020.

Based on Venture Visionary Partners's 13F filing for Q1 2020, filed 7 May 2020.